{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T23:19:48Z","timestamp":1787527188140,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"United Kingdom Research and Innovation Medical Research Council","award":["MC_UU_00040\/01"],"award-info":[{"award-number":["MC_UU_00040\/01"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["225790\/Z\/22\/Z"],"award-info":[{"award-number":["225790\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Target trial emulation prompts investigators to frame their analysis question in terms of a hypothetical clinical trial. Although this does not solve the problem of confounding, the framework can protect against other sources of bias. A natural question is this: What kinds of trials can be emulated? In a late-phase trial (phases 3 or 4), the goal is to obtain a well-defined causal estimate that closely approximates the impact of a proposed intervention. In an early-phase trial (phase 2 or earlier), the estimate is a means to an end rather than an end in itself. An early-phase trial provides proof-of-concept evidence on the impact of an intervention in the exposure in terms of efficacy and safety, but the estimand may not correspond to the intervention to be implemented in practice. In a natural experiment where causal inferences rely on a plausibly random (or quasi-random) comparison, the estimand may not be directly translatable to applied practice. In this case, the analysis may be conceptualized as an early-phase target trial. This provides less specific evidence than a late-stage target trial, but in many cases, a more valid but less applicable comparison is preferable to a more applicable comparison that is more susceptible to bias.<\/jats:p>","DOI":"10.1093\/aje\/kwag194","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:08:20Z","timestamp":1786532900000},"source":"Crossref","is-referenced-by-count":0,"title":["What phases of the drug development framework can epidemiological studies emulate?"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5365-8760","authenticated-orcid":false,"given":"Stephen","family":"Burgess","sequence":"first","affiliation":[{"name":"Medical Research Council Biostatistics Unit, University of Cambridge , Cambridge ,","place":["United Kingdom"]},{"name":"British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge , Cambridge ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1505-2570","authenticated-orcid":false,"given":"Benjamin","family":"Woolf","sequence":"additional","affiliation":[{"name":"Medical Research Council Biostatistics Unit, University of Cambridge , Cambridge ,","place":["United Kingdom"]},{"name":"Medical Research Council Integrative Epidemiology Unit, University of Bristol , Bristol ,","place":["United Kingdom"]},{"name":"School of Psychological Science, University of Bristol , Bristol ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bassett","sequence":"additional","affiliation":[{"name":"Medical Research Council Biostatistics Unit, University of Cambridge , Cambridge ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Robertson","sequence":"additional","affiliation":[{"name":"Medical Research Council Biostatistics Unit, University of Cambridge , Cambridge ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Villar","sequence":"additional","affiliation":[{"name":"Medical Research Council Biostatistics Unit, University of Cambridge , Cambridge ,","place":["United Kingdom"]},{"name":"Papworth Trials Unit Collaboration, Royal Papworth Hospital NHS Foundation Trust , Cambridge ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1028-2158","authenticated-orcid":false,"given":"Jeremy A","family":"Labrecque","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus Medical Center , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"5","key":"2026082318415465000_ref1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.2105\/AJPH.2018.304337","article-title":"The C-word: scientific euphemisms do not improve causal inference from observational data","volume":"108","author":"Hern\u00e1n","year":"2018","journal-title":"Am J Public Health"},{"issue":"7","key":"2026082318415465000_ref2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1056\/NEJMsb1901642","article-title":"The magic of randomization versus the myth of real-world evidence","volume":"382","author":"Collins","year":"2020","journal-title":"New Engl J Med"},{"issue":"8","key":"2026082318415465000_ref3","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"6","key":"2026082318415465000_ref4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10654-017-0293-4","article-title":"Target trial emulation: teaching epidemiology and beyond","volume":"32","author":"Labrecque","year":"2017","journal-title":"Eur J Epidemiol"},{"issue":"24","key":"2026082318415465000_ref5","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"2026082318415465000_ref6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2026082318415465000_ref7","doi-asserted-by":"publisher","first-page":"dyae176","DOI":"10.1093\/ije\/dyae176","article-title":"Illustrating the structures of bias from immortal time using directed acyclic graphs","volume":"54","author":"Yang","year":"2025","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2026082318415465000_ref8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/EDE.0000000000001808","article-title":"A structural description of biases that generate immortal time","volume":"36","author":"Hern\u00e1n","year":"2025","journal-title":"Epidemiology"},{"issue":"8","key":"2026082318415465000_ref9","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/aje\/kwac066","article-title":"Invited commentary: conducting and emulating trials to study effects of social interventions","volume":"191","author":"Rojas-Saunero","year":"2022","journal-title":"Am J Epidemiol"},{"key":"2026082318415465000_ref10","volume-title":"Dexamethasone for Preterm Infants at Risk of Bronchopulmonary Dysplasia: Is Timing Everything?","author":"Been","year":"2023"},{"key":"2026082318415465000_ref11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/B978-0-12-804729-3.00002-X","volume-title":"A Comprehensive and Practical Guide to Clinical Trials","author":"Wright","year":"2017"},{"issue":"1","key":"2026082318415465000_ref12","doi-asserted-by":"publisher","first-page":"e2200222","DOI":"10.1002\/bimj.202200222","article-title":"Phases of methodological research in biostatistics\u2014building the evidence base for new methods","volume":"66","author":"Heinze","year":"2024","journal-title":"Biom J"},{"issue":"21","key":"2026082318415465000_ref13","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1001\/jama.2024.7741","article-title":"Causal inference about the effects of interventions from observational studies in medical journals","volume":"331","author":"Dahabreh","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"2026082318415465000_ref14","doi-asserted-by":"publisher","first-page":"e010643","DOI":"10.1136\/bmjopen-2015-010643","article-title":"Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry","volume":"6","author":"Zhang","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"2026082318415465000_ref15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cpt.2480","article-title":"Use of real-world evidence to drive drug development strategy and inform clinical trial design","volume":"111","author":"Dagenais","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2026082318415465000_ref16","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1017\/cts.2023.635","article-title":"A causal roadmap for generating high-quality real-world evidence","volume":"7","author":"Dang","year":"2023","journal-title":"J Clin Transl Sci"},{"issue":"10","key":"2026082318415465000_ref17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.annepidem.2016.03.013","article-title":"Causal identification: a charge of epidemiology in danger of marginalization","volume":"26","author":"Schwartz","year":"2016","journal-title":"Ann Epidemiol"},{"issue":"1","key":"2026082318415465000_ref18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/ije\/dyp174","article-title":"How to assess the external validity of therapeutic trials: a conceptual approach","volume":"39","author":"Dekkers","year":"2010","journal-title":"Int J Epidemiol"},{"issue":"12","key":"2026082318415465000_ref19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1177\/01410768231207536","article-title":"The differences and overlaps between \u2018explanatory\u2019 and \u2018pragmatic\u2019 controlled trials: a historical perspective","volume":"116","author":"Glasziou","year":"2023","journal-title":"J R Soc Med"},{"issue":"9","key":"2026082318415465000_ref20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.puhe.2004.11.008","article-title":"Natural experiments: an underused tool for public health?","volume":"119","author":"Petticrew","year":"2005","journal-title":"Public Health"},{"issue":"2","key":"2026082318415465000_ref21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/1065912907306470","article-title":"Improving causal inference: strengths and limitations of natural experiments","volume":"61","author":"Dunning","year":"2008","journal-title":"Polit Res Q"},{"issue":"1","key":"2026082318415465000_ref22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/alcalc\/agx069","article-title":"The effect of increased alcohol availability on alcohol-related health problems up to the age of 42 among children exposed in utero: a natural experiment","volume":"53","author":"Thern","year":"2018","journal-title":"Alcohol Alcohol"},{"issue":"S2","key":"2026082318415465000_ref23","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/S0140-6736(16)32309-1","article-title":"Prenatal alcohol exposure and pregnancy and childhood outcomes: a systematic review of alternative analytical approaches","volume":"388","author":"Mamluk","year":"2016","journal-title":"The Lancet"},{"issue":"1","key":"2026082318415465000_ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"\u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Davey Smith","year":"2003","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2026082318415465000_ref25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"2026082318415465000_ref26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","article-title":"Mendelian randomization for studying the effects of perturbing drug targets","volume":"6","author":"Gill","year":"2021","journal-title":"Wellcome Open Res"},{"issue":"R1","key":"2026082318415465000_ref27","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: genetic anchors for causal inference in epidemiological studies","volume":"23","author":"Davey Smith","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2026082318415465000_ref28","doi-asserted-by":"publisher","first-page":"uuaf003","DOI":"10.1093\/ajeadv\/uuaf003","article-title":"The role of estimation in Mendelian randomization: should Mendelian randomization investigations provide estimates?","volume":"1","author":"Woolf","year":"2025","journal-title":"AJE Adv Res Epidemiol"},{"issue":"5","key":"2026082318415465000_ref29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/EDE.0000000000000699","article-title":"Nature as a trialist?: deconstructing the analogy between Mendelian randomization and randomized trials","volume":"28","author":"Swanson","year":"2017","journal-title":"Epidemiology"},{"issue":"12","key":"2026082318415465000_ref30","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1093\/aje\/kwaf190","article-title":"Mendelian randomization, lipids and coronary artery disease: trade-offs between study designs and assumptions","volume":"194","author":"Shi","year":"2025","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2026082318415465000_ref31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/aje\/kwy204","article-title":"Interpretation and potential biases of Mendelian randomization estimates with time-varying exposures","volume":"188","author":"Labrecque","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"S3","key":"2026082318415465000_ref32","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1038\/ijo.2008.82","article-title":"Does obesity shorten life? The importance of well-defined interventions to answer causal questions","volume":"32","author":"Hern\u00e1n","year":"2008","journal-title":"Int J Obes (Lond)"},{"key":"2026082318415465000_ref33","volume-title":"Logic (Classic Reprint): Deductive and Inductive","author":"Read","year":"2018"},{"key":"2026082318415465000_ref34","volume-title":"JLL Bulletin: Commentaries on the History of Treatment Evaluation","author":"Chalmers","year":"2023"},{"issue":"2","key":"2026082318415465000_ref35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/ije\/31.2.422","article-title":"Estimating causal effects","volume":"31","author":"Maldonado","year":"2002","journal-title":"Int J Epidemiol"},{"issue":"5","key":"2026082318415465000_ref36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/EDE.0000000000001639","article-title":"The causal effects of causal inference pedagogy","volume":"34","author":"Swanson","year":"2023","journal-title":"Epidemiology"},{"issue":"7689","key":"2026082318415465000_ref37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/d41586-018-01023-3","article-title":"Robust research needs many lines of evidence","volume":"553","author":"Munaf\u00f2","year":"2018","journal-title":"Nature"},{"issue":"6","key":"2026082318415465000_ref38","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/ije\/dyv341","article-title":"Causality and causal inference in epidemiology: the need for a pluralistic approach","volume":"45","author":"Vandenbroucke","year":"2016","journal-title":"Int J Epidemiol"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwag194\/70617095\/kwag194.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwag194\/70617095\/kwag194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T22:41:58Z","timestamp":1787524918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/advance-article\/doi\/10.1093\/aje\/kwag194\/8759474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1093\/aje\/kwag194","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"kwag194"}}